Skip to Main Content
Yale School of Medicine
YSM Home

INFORMATION FOR

Amer Zeidan, MBBS

Professor of Internal Medicine (Hematology)
DownloadHi-Res Photo

Are You a Patient?

View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.

View Doctor Profile

Additional Titles

Chief, Division of Hematologic Malignancies

Director, Early Therapeutics Research, Yale Cancer Center

Director, Leukemia and Myeloid Malignancies Program, Yale Cancer Center

Assistant Medical Director, Clinical Trials Office (CTO), Yale Cancer Center

Co-Leader, Leukemia and Myeloid Malignancies Clinical Research Team (CRT), Yale Cancer Center

About

Titles

Professor of Internal Medicine (Hematology)

Chief, Division of Hematologic Malignancies; Director, Early Therapeutics Research, Yale Cancer Center; Director, Leukemia and Myeloid Malignancies Program, Yale Cancer Center; Assistant Medical Director, Clinical Trials Office (CTO), Yale Cancer Center; Co-Leader, Leukemia and Myeloid Malignancies Clinical Research Team (CRT), Yale Cancer Center

Biography

Amer Zeidan, MBBS, MHS is a Professor of Medicine at Yale School of Medicine. He serves as the Chief of the Division of Hematologic Malignancies, Director of Hematology Early Therapeutics Research, and Assistant Director of the Clinical Trial Office for Hematology at Yale Comprehensive Cancer Center (YCC). He is also the leader of Leukemia and Myeloid malignancies Clinical Research Team. Dr. Zeidan obtained his medical degree with honors from University of Jordan, followed by residency in Rochester General hospital, Rochester, NY. He then completed a Hematology/Oncology fellowship and a clinical research fellowship in myelodysplastic syndromes (MDS) at Johns Hopkins University where he also earned a Master of Health Science (MHS) degree in Clinical Investigation. He joined Yale Faculty in 2014 where he has become an internationally recognized expert in myeloid malignancies. Dr Zeidan has been conducting research on the development of novel therapies for myelodysplastic syndromes and acute myeloid leukemia (AML) with a special focus on targeted and immunotherapy-based approaches.

Dr. Zeidan has and continues to serve as study chair and principal investigator of multiple investigator-initiated, cooperative group and industry sponsored clinical trials for myeloid malignancies. He previously served as the vice chair of the YCC Data and Safety Monitoring Committee (DSMC) and as chair of Protocol Review Committee (PRC). He has served on multiple steering committees and independent data and safety monitoring committees for randomized and registrational clinical trials. Dr. Zeidan is also a member of the MyeloMATCH Precision medicine initiative of the National Cancer Institute (NCI) for MDS and AML and is very active within the Cancer Therapy Evaluation Program (CTEP) and Early Therapy Clinical Trial Network (ETCTN) focusing on early phase clinical trials of novel therapies for myeloid malignancies.

Dr Zeidan has contributed to the approval of multiple drugs for myeloid malignancies including oral decitabine/cedazuridine (Lancet Haematology), luspatercept (NEJM and Lancet), and imetelstat (Lancet). Dr Zeidan has been active in organizing the scientific community on important initiatives including publishing a guidance on management of MDS/AML during the corona pandemic (Lancet Haematology) and revising the International Working Group response criteria for higher risk MDS (Blood Journal). He is also founder and chair of the International Consortium for MDS (icMDS) which has championed important initiatives such as harmonizing the WHO and ICC classification systems (Lancet Haematology) and standardizing eligibility for MDS clinical trials (Blood Journal). Dr Zeidan also delivered many invited talks at National and International meetings including grand rounds in several prestigious institutions.

Dr. Zeidan’s work has been recognized by several prestigious awards including the Leukemia and Lymphoma Society Scholar in Clinical Research award, the National Cancer Institute Cancer Clinical Investigator Team Leadership award, the AAMDSIF/Evan’s Foundation-MDS Clinical Research Consortium Fellowship award, the Tito Bastianello Young Investigator Award, the ASCO Young Investigator Award, and multiple other achievement awards. Dr. Zeidan also serves on the editorial board and is a reviewer of several important hematology and oncology journals. He is an author on more than 360 peer-reviewed publications and book chapters and more than 250 scientific abstracts.

Last Updated on September 25, 2023.

Appointments

  • Medical Oncology and Hematology

    Professor
    Primary

Other Departments & Organizations

Education & Training

MHS
Johns Hopkins University (2014)
Fellowship
Johns Hopkins Hospital (2013)
Internship
Rochester General Hospital (2010)
MBBS
University of Jordan (2001)

Research

Overview

The focus of my clinical/translational research is the development of novel therapies for MDS, AML, and other hematologic malignancies. Dr. Zeidan is the principal investigator on several clinical trials in MDS, AML and other hematologic malignancies. Dr. Zeidan especially focuses on the use of immunotherapies (drugs that stimulate the patient's own immune system) including the immune checkpoint inhibitors to fight blood cancers.

Clinical research; Novel therapies

Medical Research Interests

Hematologic Neoplasms; Translational Research, Biomedical

Research at a Glance

Yale Co-Authors

Frequent collaborators of Amer Zeidan's published research.

Publications

2025

See All Publications

Clinical Trials

Current Trials

Academic Achievements & Community Involvement

Activities

  • activity

    Developmental Therapeutics Research Program, Yale University

    2019 - PresentCommitteesMember
  • activity

    Cancer Outcomes, Public Policy, and Effectiveness Research Center (COPPER), Yale University

    2019 - PresentCommitteesMember
  • activity

    Yale Affiliated Hospital Program

    2015 - PresentCommitteesLecturer
  • activity

    Yale School of Medicine Internal Medicine Residency Program

    2016 - PresentCommitteesInterviewer
  • activity

    Blood Reviews

    2018 - PresentJournal ServiceEditorial Board Member
View full list of activities

Honors

  • honor

    Scholar in Clinical Research Award

    01/01/2023, 12/31/2022, 12/31/2021, 12/31/2020, 12/31/2019, 12/31/2018National AwardLeukemia and Lymphoma Society
  • honor

    Cancer Clinical Investigator Team Leadership Award

    12/31/2020, 12/31/2019, 12/31/2018National AwardNational Cancer Institute
  • honor

    Young Investigator Travel Grant

    01/01/2016, 01/01/2015Regional AwardThe Society of Oncologic Malignancy
  • honor

    Cooper Hematology Young Investigator Award

    12/31/2015Yale University Award
  • honor

    The Tito Bastianello Young Investigator Award

    12/31/2015Regional AwardThe 13th Annual International Symposium on Myelodysplastic Syndromes
View full list of honors

Clinical Care

Overview

Amer Zeidan, MBBS (a medical degree awarded in several countries outside the U.S.), MHS, is a hematologist who specializes in treating and researching myeloid malignancies.

Myeloid malignancies occur when healthy blood cells throughout the body and in bone marrow do not mature normally and instead replicate, proliferate, or transform in other ways. Dr. Zeidan’s research and clinical care focus on targeting therapies to a patient’s diagnosis and working with their own immune system to counter the malignancies.

At Yale Cancer Center, Dr. Zeidan is the medical director of Hematology Early Therapeutics Research, leader of the Disease Aligned Research Team (DART) for Leukemia and Myeloid Malignancies, and the assistant director of the Clinical Trials Office for hematology.

His research efforts focus on finding new, active, and safe therapies for blood cancers through clinical trials. He also explores why certain standard therapies have not been as effective in practice as they have been in clinical trials, and how the performance of these therapies can be improved in the clinic.

Dr. Zeidan has received many awards, including the Leukemia and Lymphoma Society Scholar in Clinical Research award and the National Cancer Institute Cancer Clinical Investigator Team Leadership award. He serves on the editorial boards of several key hematology and oncology publications, and is the author of more than 260 peer-reviewed studies and chapters of books.

Clinical Specialties

Hematologic Oncology; Hematology

Fact Sheets

See All Fact Sheets On Yale Medicine

Yale Medicine News

See All News On Yale Medicine

Are You a Patient?

View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.

View Doctor Profile

Get In Touch

Contacts

Appointment Number
Clinic Fax Number

Administrative Support

Locations

  • 37 College Street

    Academic Office

    Fl 1, Rm 101

    New Haven, CT 06510

    Get Directions

  • Patient Care Locations

    Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.

    See Patient Care Locations

Events

Jul 202526Saturday